As per the WHO, every year around 2.1 million women are detected with breast cancer. It is
one of the most invasive cancer in women and second most among all, contributing around …

The study of protein–nanoparticle interactions provides knowledge about the bio-reactivity of
nanoparticles, and creates a database of nanoparticles for applications in nanomedicine …

Highlights•Breast cancer (BC) is the most aggressive malignant cancer in women
worldwide.•Multidrug resistance (MDR), poor targeting, and high toxicity constrain …

Highlights•HER2 is overexpressed in a variety of solid tumours.•An overview of HER2 in
cancer signalling is highlighted.•Various HER2 targeted delivery strategies have been …

Targeted drug delivery is one of the most intriguing and challenging issues in modern
biomedicine. For active targeting, full-size IgG molecules (150 kDa) are usually used …

Simple Summary Drug resistance is the “Achilles' heel” in current oncology. In this sense,
the clinical management of HER2 breast carcinomas (tumors with overexpression …

Introduction Breast carcinoma (BC) is one of the most frequent causes of cancer-related
death among women, which is due to the poor response to conventional therapy. There are …

Simple Summary The use of nanopharmaceuticals in chemotherapeutic regimens has
become a promising approach for the treatment of most of the demanding types of cancers …

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for
about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor …

Peptidases are emerging as promising drug targets in tumour suppression. Neprilysin, also
known as neutral endopeptidase, is a cell surface peptidase that degrades various peptides …